. . . "Nov\u00E9 mo\u017Enosti syst\u00E9mov\u00E9 l\u00E9\u010Dby karcinomu ledviny" . "12" . . . "Petru\u017Eelka, Lubo\u0161" . "Nov\u00E9 mo\u017Enosti syst\u00E9mov\u00E9 l\u00E9\u010Dby karcinomu ledviny"@cs . "Nov\u00E9 mo\u017Enosti syst\u00E9mov\u00E9 l\u00E9\u010Dby karcinomu ledviny" . "Postgradu\u00E1ln\u00ED medic\u00EDna" . "V" . . . . "1212-4184" . "275297" . . "New options for systemic treatment of renal cell cancer"@en . "2"^^ . . "CZ - \u010Cesk\u00E1 republika" . "Z\u00E1kladem l\u00E9\u010Dby lokalizovan\u00E9ho karcinomu ledviny je operace.L\u00E9\u010Dba pokro\u010Dil\u00FDch a metastazuj\u00EDc\u00EDch st\u00E1di\u00ED spo\u010D\u00EDv\u00E1 v pod\u00E1v\u00E1n\u00ED cytokin\u016F, kter\u00E9 m\u016F\u017Ee b\u00FDt prosp\u011B\u0161n\u00E9 u nemocn\u00FDch v dobr\u00E9 prognostick\u00E9 skupin\u011B." . "New options for systemic treatment of renal cell cancer"@en . . "The basis for treatment of localized renal cancer is surgery. The treatment of advanced and metastatic stages consists of cytokines administration, which may be beneficial in patients from the good prognostic group."@en . . . . "2"^^ . . . "RIV/00064165:_____/10:7545" . "6"^^ . "Z\u00E1kladem l\u00E9\u010Dby lokalizovan\u00E9ho karcinomu ledviny je operace.L\u00E9\u010Dba pokro\u010Dil\u00FDch a metastazuj\u00EDc\u00EDch st\u00E1di\u00ED spo\u010D\u00EDv\u00E1 v pod\u00E1v\u00E1n\u00ED cytokin\u016F, kter\u00E9 m\u016F\u017Ee b\u00FDt prosp\u011B\u0161n\u00E9 u nemocn\u00FDch v dobr\u00E9 prognostick\u00E9 skupin\u011B."@cs . "Zemanov\u00E1, Milada" . "[C7EC3C9B4EE1]" . . "3" . . "RIV/00064165:_____/10:7545!RIV11-MZ0-00064165" . "Renal cancer; sorafenib; sunitinib; bevacizumab; pazopanib; everolimus"@en . "Nov\u00E9 mo\u017Enosti syst\u00E9mov\u00E9 l\u00E9\u010Dby karcinomu ledviny"@cs .